A 29-day, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
Phase of Trial: Phase II
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Daprodustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 17 Apr 2017 Status changed from active, no longer recruiting to completed.
- 21 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017.